Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denileukin diftitox - Eisai

Next Previous
X
Search
Drug Profile

Denileukin diftitox - Eisai

Alternative Names: DAB389IL-2; DAB389 interleukin-2; E7272; E7777; I/ONTAK; Interleukin-2 fusion toxin; LY 335348; LYMPHIRTM; ONTAK; Remitoro

Latest Information Update: 20 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto; Japanese Foundation for Cancer Research
  • Developer Citius Oncology; Eisai Co Ltd
  • Class ADP ribose transferases; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antiretrovirals; Antirheumatics; Bacterial toxins; Interleukins; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
  • Phase II Malignant melanoma
  • Phase I/II Diffuse large B cell lymphoma
  • Discontinued Alopecia; Atopic dermatitis; HIV infections; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 12 Aug 2024 Citius Pharmaceuticals completes the spin-off of denileukin diftitox into its majority-owned oncology company, Citius Oncology
  • 08 Aug 2024 Registered for Cutaneous T-cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 08 Aug 2024 Citius Pharmaceuticals plans to launch denileukin diftitox for Cutaneous T-cell lymphoma (Second-line therapy or greater) in the USA in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top